ADMINISTRATIVE, MANAGEMENT AND SUPERVISORY BODIES AND SENIOR MANAGEMENT 14 Mr. Collier has resigned from the Board of Directors and has been the Board of Directors deemed relevant in determining the replaced by Ms. Seiter on April 19, 2017. director’s independence, including the number of ordinary shares Ms. Mount joined the Board of Directors on May 31, 2017. beneficially owned by the director and his or her affiliated entities, if any. Mr. Lloyd-Harris has resigned from the Board of Directors on March 16, 2018. 14.1.2 BIOGRAPHICAL INFORMATION ABOUT The table below gives the identity of our non-voting observers are THE MEMBERS OF THE BOARD OF DIRECTORS AND also attending board meetings as of the date of this Registration OFFICERS OF THE COMPANY Document: Officers Name Expiration date of term of office Bernard Gilly, Ph.D., one of our founders, has served as our Chief José-Alain Sahel 2021 Executive Officer since our creation. From our creation through Thibaut Roulon 2019 2016, Dr. Gilly served as Chairman of our Board of Directors. From 2011 through 2014, Dr. Gil ly served as Chief Executive Laurent Higueret 2020 Officer at Pixium Vision and from which date he has served as Separation of the Offices of Chairman of the Board and Chief non-executive Chairman of the Board of Directors. Additionally, Executive Officers Mr. Gil ly currently serves on the boards of Prophesee S.A. (formerly Chronocam) and Gecko Biomedical. From 2005 to On March 2, 2016, our Board of Directors decided to separate 2009, he founded and was Chairman and Chief Executive Officer the offices of the Chairman of the Board of Directors and of of Fovea Pharmaceuticals S.A., or Fovea, a privately funded the Chief Executive Officer. As of the date of this Registration biotech company, which was acquired by Sanofi S.A., or Sanofi. Document, Bernard Gil ly is Co-Founder, Director and Chief He then became Senior Vice-President of the Ophthalmology Executive Officer and Michael Wyzga is the Chairman of our Division of Sanofi and served in that role until March 2012. Prior Board of Directors. to Fovea, Dr. Gil ly was a partner at Sofinnova Partners S.A.S. Director Independence from December 2000 to November 2005. From January 1992 to October 2000, he was Chief Executive Officer of Transgene S.A., We consider that, under the recommendations of the MiddleNext a company listed on the NASDAQ stock exchange and the Code, four current directors are “independent directors.” Nouveau Marché of Euronext Paris, France. Dr. Gilly received an The MiddleNext Code sets out the five following criteria justifying engineering degree from École Nationale d’Agronomie and a the independence of directors, characterized by the absence of Ph.D. from Université de Rennes. any significant financial, contractual or family relationship likely toThomas Gidoin has been our Chief Financial Officer since affect their independence of judgment: June 2015. From 2012 to mid-2015, Mr. Gidoin was Vice • they must not be a salaried employee or corporate officer of us President Finance at DBV Technologies S.A., where he led the or our group and must not have held such a position within the Corporate Finance team and participated in public offerings last five years; and private placements, including the dual listing of DBV • they must not be in a significant business relationship with us Technologies S.A. on the NASDAQ Global Select Market in 2014. or our group (e.g., client, supplier, competitor, provider, creditor,From 2008 to 2011, Mr. Gidoin served in various positions at banker, etc.) within the last two years; Ipsen S.A., including UK Operations Controller in London and • they must not be a reference shareholder or hold a significant Senior Financial Analyst in the Global Operations division in number of voting rights; Paris. He started his career in audit at Ernst & Young. Mr. Gidoin received a Master’s degree in International Finance from ESGF • they must not have close relationships or family ties with any of Paris and a Master’s degree in International Management from our corporate officer or reference shareholder; and Neoma Business School in France. • they must not have been our auditor within the last six years. MBA has served as our Chief Medical Officer Barrett Katz, M.D, Based on these criteria, our Board of Directors determined since November 2017. Prior to joining GenSight, Dr. Katz was the that Mr. Wyzga, Dr. Seiter, Ms. Mount and Dr. Goodfellow are Francis DeJur Chair of Ophthalmology at the Montefiore Medical “independent directors” under the independence criteria of the Center and Albert Einstein Col lege of Medicine in New York MiddleNext Code. In making such determination, the Board of where he also served as Professor of Ophthalmology, Neurology Directors considered the relationships that each non-employee and Neurosurgery, and the Executive Director of Clinical Trials director has with us and al l other facts and circumstances from, January 2010 to October 2017. He has been engaged in 148– GENSIGHT BIOLOGICS – 2017 Registration Document